Australia's Soft Landing Spurs Debate Over Policy in Next Crisis
Through the post-Covid cost-of-living crisis, Australia's central bank took a gentler approach than global peers to reining in inflation, managing to keep the economy close to full employment throughout — a rare feat that's sparked debate about its viability as a model to tackle future crises.
With inflation now back in its target zone, the Reserve Bank of Australia on Tuesday reduced its key rate by a quarter percentage point for a second time in the current easing cycle to 3.85%. Across the Tasman Sea, by contrast, the Reserve Bank of New Zealand has slashed its benchmark rate by 2 percentage points to 3.5% after taking a more conventional approach with more aggressive hikes to quell price gains.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
BOJ's Ueda Helps Nudge Yen Weaker as Traders Twitch on Comments
Bank of Japan Governor Kazuo Ueda said the central bank is still some distance from its inflation goal in comments that helped accelerate a weakening of the yen. While Ueda also talked down the possibility of any rate cut to boost the economy, the mention of a possible need to offer support for the economy likely gave the impression that the bank's next move to raise rates will be more distant.
Yahoo
an hour ago
- Yahoo
ASX Penny Stocks: Frontier Digital Ventures And 2 Other Promising Picks
As the Australian market eases back into action after a brief hiatus, investors are keenly observing developments both locally and internationally, with trade talks and economic reports shaping the landscape. Despite being an older term, "penny stocks" continue to hold relevance for those looking to uncover growth opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer attractive potential returns at lower price points, making them intriguing options for discerning investors. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,003 stocks from our ASX Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Frontier Digital Ventures Limited is a private equity firm focused on investing in and developing online classifieds businesses in emerging markets, with a market cap of A$99.75 million. Operations: Frontier Digital Ventures generates revenue from its online classifieds businesses across various regions, with notable contributions from Infocasas (A$19.43 million), Fincaraiz (A$14.14 million), Encuentra24 (A$11.65 million), and Avito (A$7.66 million). Market Cap: A$99.75M Frontier Digital Ventures has a market cap of A$99.75 million and focuses on online classifieds in emerging markets, generating significant revenue from businesses like Infocasas and Fincaraiz. Despite being unprofitable, it maintains a strong cash position with short-term assets exceeding liabilities, allowing for over a year of runway based on current free cash flow. The company has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt. Recent board changes include the appointment of Patrick Grove as Director, which may influence strategic direction amidst high share price volatility. Jump into the full analysis health report here for a deeper understanding of Frontier Digital Ventures. Gain insights into Frontier Digital Ventures' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Imugene Limited is a clinical stage immuno-oncology company in Australia that develops immunotherapies aimed at activating the immune system to treat and eradicate cancerous tumors, with a market cap of A$119.47 million. Operations: Imugene generates its revenue from the research, development, and commercialisation of health technologies, with reported earnings of -A$1.84 million. Market Cap: A$119.47M Imugene Limited, with a market cap of A$119.47 million, is a clinical-stage immuno-oncology company that remains pre-revenue, generating less than US$1 million. Despite being unprofitable and not expected to reach profitability in the next three years, Imugene's short-term assets significantly exceed both its short and long-term liabilities. The company has more cash than debt but faces a limited cash runway of 3-4 months based on past free cash flow estimates. Recent developments include its addition to the S&P/ASX Emerging Companies Index and presentations at industry conferences by CEO Leslie Chong. Dive into the specifics of Imugene here with our thorough balance sheet health report. Review our growth performance report to gain insights into Imugene's future. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties with a market capitalization of A$560.50 million. Operations: The company's revenue is primarily generated from its Chatree segment, which reported A$210.69 million. Market Cap: A$560.5M Kingsgate Consolidated, with a market cap of A$560.50 million, demonstrates strong financial performance in the penny stock category. The company has shown impressive earnings growth of 1203% over the past year, significantly outpacing industry averages. Its debt management is robust, with operating cash flow covering 69% of its debt and EBIT covering interest payments 17.2 times over. Recent announcements include a share buyback program aimed at enhancing shareholder value as part of its capital management strategy. However, while short-term liabilities are covered by assets, long-term liabilities remain uncovered by current short-term assets. Unlock comprehensive insights into our analysis of Kingsgate Consolidated stock in this financial health report. Explore Kingsgate Consolidated's analyst forecasts in our growth report. Unlock our comprehensive list of 1,003 ASX Penny Stocks by clicking here. Seeking Other Investments? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:FDV ASX:IMU and ASX:KCN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
